Oncology Pharma, Inc. is an oncology company. The Company is focused on licensing, developing, manufacturing and commercializing therapeutics. The Companyâ€™s research, development, and commercialization of therapeutic drugs and medical devices designed for the treatment of many types of cancers. The Company offers a portfolio, such as Nanosmart Pharmaceuticals Inc. (Nanosmart Pharmaceuticals). The Companyâ€™s NanoSmart platform technology is a human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors. Its anti-cancer drugs in combination with medications, for treating a variety of cancers, such as breast, ovarian, lung, bladder, Kaposi's sarcoma, lymphoma and acute lymphocytic leukemia is doxorubicin. Its portfolio also includes Connect2Med, Sybleu, Inc. and Regen.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	19.8L 17.26L 16.35L 14.79L 27.69L 19Cr 27.92L 1.95Cr 75.23L 9.63Cr 74.35L 72.7L 31Cr	P/E 2003 *	-	P/E 2004	-
Enterprise Value	19.8L 17.26L 16.35L 14.79L 27.69L 19Cr 27.92L 1.95Cr 75.23L 9.63Cr 74.35L 72.7L 31Cr	EV / Sales 2003	-	EV / Sales 2004	-
Free-Float	100%	Yield 2003 *	-	Yield 2004	-

02/24/02	Krystal Biotech, Inc. : Will it go even higher?
31/21/31	NanoSmart Pharmaceuticals, Inc. announced that it has received funding from Oncology Pharma Inc.	CI
10/21/10	Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy	CI
04/21/04	Oncology Pharma Inc. Moves to Fund Lead Drug Formulation & IND-Enabling Studies	CI
26/21/26	Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent	CI
22/21/22	Oncology Pharma Extends Licensing Agreement with Nanosmart Pharmaceuticals, Inc. for Veterinary Oncology	CI
16/21/16	Oncology Pharma Inc. Announces Henry Smith as New Chairman to Its Scientific Advisory Board	CI
09/21/09	Oncology Pharma Renews Licensing Agreement with Ribera Solutions LLC for Its Connect2med Clinical Trials Platform	CI
29/21/29	Oncology Pharma Announces the Appointment of James Smith as New Chief Financial Officer	CI
11/20/11	Oncology Pharma Inc. cancelled the acquisition of acquire 50% stake in Diagnomics, Inc.	CI
06/20/06	Oncology Pharma and Kalos Therapeutics Expand Licensing Agreement for Exploring Kalos's Anti-Cancer Lead Drug in Treating Covid-19	CI
20/19/20	Oncology Pharma Inc. announced that it expects to receive $38.4 million in funding from SCP Partners	CI
11/19/11	Oncology Pharma Inc. signed a Letter of Intent to acquire 50% stake in Diagnomics, Inc.	CI

12/22/12	Oncology Pharma : Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System	PU
29/22/29	Oncology Pharma : Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System	PU
06/22/06	Oncology Pharma : Financial Statements (Unaudited) for the year ended March 31, 2022	PU
15/22/15	Oncology Pharma : Financial Statements for the period ended December 31, 2021	PU
15/22/15	Oncology Pharma : Disclosure Statement for the period ended December 31, 2021	PU

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SOURCINGLINK.NET, INC.	-.--%	+9.50%	-	-	19.8L
ELI LILLY AND COMPANY	+0.15%	+1.24%	+52.08%	+97.65%	1,01300Cr
JOHNSON & JOHNSON	+0.03%	-0.68%	+50.67%	+65.55%	64TCr
ABBVIE INC.	-0.20%	+5.52%	+20.63%	+72.57%	46TCr
ROCHE HOLDING AG	+0.53%	+3.42%	+39.21%	+38.70%	35TCr
NOVARTIS AG	+0.39%	+2.22%	+17.02%	+23.87%	26TCr
ASTRAZENECA PLC	+0.17%	+2.19%	+6.33%	+10.93%	25TCr
AMGEN INC.	+0.19%	-4.28%	+37.15%	+44.35%	20TCr
NOVO NORDISK A/S	-1.20%	-6.64%	-23.23%	-59.10%	19TCr
GILEAD SCIENCES, INC.	+0.94%	+0.71%	+31.22%	+95.16%	18TCr
Average	+0.10%	-1.08%	+25.67%	+43.30%	39.6TCr
Weighted average by Cap.	+0.11%	+0.01%	+34.70%	+59.67%

	2003	2004
Net sales	32.8L 28.6L 27.09L 24.51L 45.88L 31Cr 46.26L 3.23Cr 1.25Cr 16Cr 1.23Cr 1.2Cr 51Cr	11.81L 10.3L 10L 9L 16.52L 11Cr 16.66L 1.16Cr 44.88L 5.75Cr 44.36L 43.37L 18Cr
Net income	-15.2L -13.25L -12.55L -11.36L -21.26L -15Cr -21.44L -1.5Cr -57.77L -7.4Cr -57.09L -55.82L -24Cr	-15.65L -13.65L -12.92L -11.69L -21.89L -15Cr -22.07L -1.54Cr -59.48L -7.61Cr -58.78L -57.48L -24Cr
Net Debt	-13.46L -11.74L -11.12L -10.06L -18.83L -13Cr -18.98L -1.33Cr -51.15L -6.55Cr -50.56L -49.43L -21Cr	17T 14.82T 14.04T 12.7T 23.78T 16.31L 23.98T 2L 64.61T 8L 63.85T 62.43T 26.55L

SourcingLink.net, Inc. Share Price OTC Bulletin Board

Stocks

US8361714053

Pharmaceuticals

Valuation: SourcingLink.net, Inc.

Latest news: SourcingLink.net, Inc.

Press Releases: SourcingLink.net, Inc.

News in other languages: SourcingLink.net, Inc.

Managers and Directors: SourcingLink.net, Inc.

Other Pharmaceuticals

Financials

Company Profile